• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

    3.110 +1.110 (+55.50%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Esperion Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    News headline image
    Top 2 Health Care Stocks That May Plunge This Month ↗
     
    Via Benzinga
    News headline image
    Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in Upcoming September Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For August 5, 2025 ↗
     
    Via Benzinga
    News headline image
    What to Expect from Esperion Therapeutics's Earnings ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For May 6, 2025 ↗
     
    Via Benzinga
    News headline image
    Esperion (ESPR) Q2 Revenue Jumps 12% ↗
    Via The Motley Fool
    News headline image
    Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth ↗
    Esperion Therapeutics (ESPR) beats Q2 2025 revenue estimates with $82.4M, narrows losses, and sees 42% U.S. sales growth. Stock surges 12% pre-market. 
    Via Chartmill
    News headline image
    Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Report Second Quarter 2025 Financial Results on August 5
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Appoints Craig Thompson to Board of Directors
    Brings More Than Twenty Years of Biopharmaceutical Leadership Experience 
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in Upcoming June Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Reports First Quarter 2025 Financial Results
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗
    Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
    Via Stocktwits
    Topics Stocks
    News headline image
    Esperion to Participate in The Citizens Life Sciences Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Report First Quarter 2025 Financial Results on May 6
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
    Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases 
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Appoints Robert E. Hoffman to Board of Directors
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 ↗
    CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key... 
    Via Stocktwits
    News headline image
    Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.